Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: sector’s upside is paying a toll to roll forward

November 2, 2020 5:43pm

What’s protection from tomorrow’s outcomes?

Pre-open indication results: 5 HITs and 1 Miss

An “intelligence newspaper” for smart investing in the RegMed, gene and cell therapy sector. I track the numbers, so there’s no question re my opinion; so, you can do what others can't.

Subscription is coming, my gift to you: I've kept RMi subscription FREE during these COVID-19 and volatile times!

The Dow closed UP +423.45 points (+1.60%), the S&P closed UP +40.28 points (+1.23%) while the Nasdaq closed UP +46.02 points (+0.42%)

Henry’omics:

Indexes jumped on Monday on the first trading day of the month, as markets recovered some of the losses from last week and braced for tomorrow’s U.S. presidential election.

We are all waiting for the results of the presidential and senate election as major averages came-off their worst week since March, coronavirus cases surged, fiscal stimulus negotiations fell apart and quarterly earnings reports wilted.

Pre-open indication: 5 HITs < Biostage (BSTG -$0.00), Alnylam Pharmaceuticals (ALNY +$1.94), Brainstorm Cell Therapeutics (BCLI +$0.59); Sell into Strength: Ultragenyx (RARE -$4.97) Bellicum Pharmaceuticals (BLCM -$0.43), > and 1 MISS < Applied Genetic Technologies (AGTC -$0.01)>

This morning, I stated in this a.m.’s newsletter – RegMed Investors’ (RMi) pre-open: RegMed Investors’ (RMi) pre-open: what’s motivating outcomes - speculation and shots in the dark … https://www.regmedinvestors.com/articles/11615

RegMed/Cell and Gene therapy 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …

Monday opened positive at 23/8 and 4 flats, strayed negative at the mid-day at 9/23 and 3 flats, closing positive at 17/15 and 3 flats;
Friday opened negative at 6/26 and 3 flats, stayed negative at the mid-day at 3/30 and 2 flats, closing negative at 5/28 and 2 flats;

Key metrics:

Sector volume was the usual LOW with 7 of the 17-upside having higher than the 3-month average volume with the increased volume of 5 of 15-downside having higher than the 3-month average volume;

Monday’s percentage (%) of the 17-upside were +0.19% (VYGR) to +14.66% (MDXG) while the 15-downside of -0.11% (PSTI) to -11.59% (BLCM);

Hammered in today’s market:

CRISPR Therapeutics (CRSP), Ultragenyx (RARE), ReNeuron (RENE.L), Sage Therapeutics (SAGE), Regenxbio (RGNX) to name 5 of the 15 declining of the 35 covered

Jumping with share pricing momentum:

Alnylam Pharmaceuticals (ALNY), bluebird bio (BLUE), BioLife Solutions (BLFS), MiMedx (OTC Pink sheets: MDXG), Chinook Therapeutics (KDNY) to name 5 of the 17 inclining of the 35 covered

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

Monday, the IBB closed down -0.18% and XBI closed down -0.01%
Friday, the IBB closed down -1.83 % and XBI closed down -2.12 %

Monday’s (10 of 17) incliners:

Alnylam Pharmaceuticals (ALNY +$1.94);
bluebird bio (BLUE+$1.38 after Friday’s -$0.96)
Chinook Therapeutics (KDNY +$1.03 after Friday’s +$0.45);
BioLife solutions (+$0.85);
MiMedx (OTC Pink sheets: MDXG +$0.78);
Brainstorm Cell Therapeutics (BCLI +$0.59 after Friday’s -$0.72);
Vericel (VCEL +$0.55);
uniQure NV (QURE +$0.44 after Friday’s +$0.18);
Adverum Biotechnologies (ADVM +$0.43);
Intellia Therapeutics (NTLA +$0.38 after Friday’s -$1.01);

Monday’s (10 of 15) decliner:

CRISPR Therapeutics (CRSP -$5.66 after Friday’s -$4.53);
Ultragenyx (RARE -$4.97 after Friday’s +$5.50 - an all-time high);
ReNeuron (RENE.L -$4.00);
Sage Therapeutics (SAGE -$1.70 after Friday’s -$0.53);
Regenxbio (RGNX -$0.83 after Friday’s -$0.56);
Fate Therapeutics (FATE -$0.46 after Friday’s -$1.23);
Bellicum Pharmaceuticals (BLCM -$0.43 after Friday’s -$2.19);
Global Blood Therapeutics (GBT -$0.41);
Homology Medicine (FIXX -$0.25);
Ionis Pharmaceuticals (IONS -$0.18 after Friday’s +$0.10);

Closing flat - 3 –Biostage (BSTG), Caladrius Biosciences (CLBS) and 1 -Stemline Therapeutics (STML – acquired)

Percentage (%) movement/range statistics: a 360 degrees comparison of % and pricing

Monday’s percentage (%) of the 17-upside were +0.19% (VYGR) to +14.66% (MDXG) while the 15-downside of -0.11% (PSTI) to -11.59% (BLCM);
Friday’s percentage (%) of the 5-upside were +0.21% (IONS) to +5.79% (RARE) while the 28-downside ranges from -0.28% (ALNY) to -37.12% (BLCM);

Sentiment and a few daily indicators:

Sentiment is floating like a butterfly in the winds of momentum and electoral politics.

Infection cases <Million>:

Monday 9.2 M cases
Friday 8.99 cases

Monday’s death rate totaled 231,011 after Friday’s 229,141, Thursday’s 227,706, Wednesday’s 226,777, Tuesday’s 226,436 and Monday’s 225,434 <Johns Hopkins University>

Stats:

Upside volume:

Monday: 7 out of the 17-upside had higher than the 3-month average volume;
Friday: 1 out of the 5-upside had higher than the 3-month average volume;

The CBOE Volatility Index (VVIX: INDEX) tracked:

Monday was down -0.89 points or -2.34% at 37.13
Friday was up +0.43 points or +1.14% at 38.02

Downside volume:

Monday: 5 out of the 15-downside had higher than the 3-month average volume;
Friday: 3 out of the 28-downside had higher than the 3-month average volume;

November, the 2^nd month of Q4 …

Monday (11/2) closed positive with 17 advancers, 15 decliners and 3 flats

The Bottom Line: The world’s markets are in a holding pattern as investors await clarity on the U.S. election, I have been right on the mark in reiterating, bubble, bubble; the market and sector are getting chewed!

Now we enter the big upswing in sector earnings’ LPS (loss-per-share) releases with the next month likely to remain volatile and uncertain.

Until then, I’d keep the lid on your portfolio if you haven’t reduced risk and sit with your back to the wall … to see what’s coming before you!

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.